PuraPharm Corporation Limited (HKG:1498)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.3300
+0.0200 (6.45%)
At close: Mar 10, 2026
Market Cap176.57M -15.7%
Revenue (ttm)346.76M -17.3%
Net Income-38.56M
EPS-0.10
Shares Out535.05M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume79,000
Average Volume142,100
Open0.3100
Previous Close0.3100
Day's Range0.3100 - 0.3400
52-Week Range0.3000 - 0.6500
Beta0.10
RSI49.62
Earnings DateMar 30, 2026

About PuraPharm Corporation

PuraPharm Corporation Limited, an investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers over the counter health products under the PuraGold, Oncozac, Haveron, and Immuzac brand names. It also provides Chinese medicine clinic management system for general... [Read more]

Sector Healthcare
Founded 1998
Employees 469
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1498
Full Company Profile

Financial Performance

In 2024, PuraPharm Corporation's revenue was 382.09 million, a decrease of -6.09% compared to the previous year's 406.86 million. Losses were -35.44 million, -66.59% less than in 2023.

Financial Statements